Free Trial
NYSE:PFE

Pfizer (PFE) Stock Price, News & Analysis

$28.56
+0.05 (+0.18%)
(As of 09/6/2024 ET)
Today's Range
$28.28
$28.77
50-Day Range
$27.67
$31.38
52-Week Range
$25.20
$34.64
Volume
31.21 million shs
Average Volume
38.33 million shs
Market Capitalization
$161.84 billion
P/E Ratio
N/A
Dividend Yield
5.88%
Price Target
$34.54

Pfizer MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
20.9% Upside
$34.54 Price Target
Short Interest
Healthy
1.09% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.68
Upright™ Environmental Score
News Sentiment
0.62mentions of Pfizer in the last 14 days
Based on 29 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.14%
From $2.66 to $2.85 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.91 out of 5 stars

Medical Sector

16th out of 910 stocks

Pharmaceutical Preparations Industry

6th out of 426 stocks

PFE stock logo

About Pfizer Stock (NYSE:PFE)

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

PFE Stock Price History

PFE Stock News Headlines

2 Election-Proof Dividends Growing Up to 67%
How about two bold election predictions—and two payouts that will thrive regardless of the results? My first forecast: Americans will still want to ea
3 Bargain-Priced Growth Stocks for Fall 2024
3 Bargain-Priced Growth Stocks for Fall 2024
Investors can leverage market volatility to uncover undervalued companies with solid fundamentals and significant growth potential.
Kamala’s Dirty Election Move… Revealed
According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move…
weight loss injection with measuring tape Eli Lilly
Eli Lilly’s Path to the Next Trillion Market Capitalization (PFE)
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Ford logo on orange car
These 3 Stocks Pay You More Than 5% to Own Them (PFE)
High dividend yields paired with fundamentally sound and undervalued stocks provide opportunities for both income and long-term capital appreciation.
house frame new construction
Value Investing: Unearthing 3 Hidden Gems in Today's Market (PFE)
Discover undervalued companies and build long-term wealth through the insightful strategy of value investing.
In this photo The logo of Merck and Co, Inc.Merck is an American multinational pharmaceutical company
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why (PFE)
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
syringe and vaccine in hand
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (PFE)
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Kamala’s Dirty Election Move… Revealed
According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move…
(AP Illustration/Jenni Sohn)
Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world
Novavax stock price forecast
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp? (PFE)
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
Why Pfizer Investors Should Closely Monitor VAX-31
Pfizer: Cheap For A Reason, But I Remain Bullish
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/14 Dividend
5/09/2024
Dividend Payable
6/14/2024
Ex-Dividend for 9/3 Dividend
7/26/2024
Last Earnings
7/30/2024
Dividend Payable
9/03/2024
Today
9/07/2024
Next Earnings (Estimated)
10/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$34.54
High Stock Price Target
$45.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+20.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$55.17 billion
Cash Flow
$2.93 per share
Book Value
$15.81 per share

Miscellaneous

Outstanding Shares
5,666,593,000
Free Float
5,663,193,000
Market Cap
$161.84 billion
Optionable
Optionable
Beta
0.68

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer's recent dividend announcement of $0.42 per share represents a solid annualized dividend yield of 5.79%, providing investors with a steady income stream.
  • Analysts have raised their target price on Pfizer, indicating positive sentiment and potential for stock price appreciation.
  • Pfizer's strong quarterly earnings report, beating consensus estimates, showcases the company's financial health and growth potential.
  • Recent analyst ratings upgrades from "moderate buy" to "strong buy" suggest increasing confidence in Pfizer's future performance.
  • Pfizer's diverse portfolio of biopharmaceutical products positions the company well for long-term growth and stability in the healthcare sector.

Cons

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Pfizer's current stock price has a negative P/E ratio, indicating that the company's earnings are not sufficient to support the stock price, which may raise concerns about overvaluation.
  • The company's payout ratio of -2,800.00% raises questions about the sustainability of its dividend payments and financial management practices.
  • While Pfizer has shown growth potential, the biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Pfizer's future performance.
  • Market volatility and macroeconomic factors could affect Pfizer's stock price, leading to potential short-term fluctuations in investment returns.
  • Investors should consider the impact of Pfizer's debt-to-equity ratio of 0.65 on the company's financial leverage and risk profile when making investment decisions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 3, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

PFE Stock Analysis - Frequently Asked Questions

How have PFE shares performed this year?

Pfizer's stock was trading at $28.79 at the beginning of 2024. Since then, PFE stock has decreased by 0.8% and is now trading at $28.56.
View the best growth stocks for 2024 here
.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings data on Tuesday, July, 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm's quarterly revenue was up 2.1% compared to the same quarter last year.
Read the conference call transcript
.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Pfizer have any subsidiaries?

Pfizer subsidiaries include ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others.

Who are Pfizer's major shareholders?

Top institutional shareholders of Pfizer include Massachusetts Financial Services Co. MA (1.27%), Legal & General Group Plc (0.82%), Bank of New York Mellon Corp (0.74%) and Dimensional Fund Advisors LP (0.59%). Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico, Scott Gottlieb, Alexander R Mackenzie, John D Young and Douglas M Lankler.
View institutional ownership trends
.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV) and Walt Disney (DIS).

This page (NYSE:PFE) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners